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ABSTRACT
Background: The use of misoprostol in the management of first trimester abortion is an evolving clinical practice in most 
parts of sub‑Saharan Africa.
Objective: To determine the effectiveness and acceptability of misoprostol in the evacuation of the uterus in first trimester 
missed abortion.
Study Design: This was a non‑randomized trial.
Setting: This study was conducted in the Gynecologic Unit, Abubakar Tafawa Balewa University Teaching Hospital Bauchi, 
Nigeria.
Materials and Methods: Consented consecutive patients with first trimester missed abortion were recruited in the study. 
Each patient was given sublingual misoprostol 600 µg to be repeated after 6 hours if abortion process was not initiated. 
They were followed‑up after two weeks and offered contraceptive counseling. However, if active vaginal bleeding persisted, 
patients were reviewed after 1 week, scanned and offered surgical evacuation (manual vacuum aspiration) on confirmation of 
residual products of conception. Telephone review was conducted for patients who defaulted follow‑up. Data were analyzed 
using the Statistical Package for the Social Sciences version 16. P value was considered significant at α < 0.05 at 95% CI.
Results: Sixty‑one patients with missed abortion were managed between 1st January and December 2013 with a mean 
age, parity and gestational age of 27.6 ± 5.6 years, 3.6 ± 2.3 and 7.6 ± 2.0 weeks, respectively. Fifty‑six patients (92%) 
achieved complete evacuation. Mean interval between the first dose of misoprostol and abortion was 5.1 ± 2.2 hours and 
mean duration of vaginal bleeding was 5.9 ± 1.6 days (range: 3–14 days). Side effects were minor mainly nausea/vomiting, 
and all the patients with complete evacuation showed satisfaction with the method and preferred it to surgical evacuation.
Conclusion: Misoprostol is very effective in the management of first trimester missed abortion in our setting and should be 
the treatment method of first choice.
Key words: Evacuation; first trimester; misoprostol; missed abortion; pregnancy; products of conception.
Introduction
Misoprostol‑a prostaglandin E1 analogue has emerged as one 
of the most important medication in obstetrics. It is useful 
in every trimester of pregnancy including the postpartum 
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period. It is effective in the management of first trimester 
abortion and has increased access to post‑abortion care 
particularly in developing countries where abortion laws are 
restrictive.[1‑4] It is also effective in the treatment of second 
trimester abortion, induction of labour and prevention and 
treatment of postpartum heamorrhage.[1]
One of the profound advantages of misoprostol over other 
prostaglandins is that it is stable at room temperature, 
and hence does not require refrigeration for storage. This 
pharmacodynamic characteristic or property of misoprostol 
is relevant in our setting where electricity supply is a luxury. 
Other advantages of misoprostol include its robust route 
of administration (oral, buccal, intravaginal and rectal), 
availability and low cost.
Although misoprostol when given alone is not as effective as 
when combined with mifepristone in the termination of first 
trimester viable pregnancies,[1‑4] there is evidence indicating 
that it is very effective in the evacuation of first trimester 
pregnancy failure (missed abortion) and incomplete abortion 
in both resource rich and poor settings.[5‑9] Reports from 
Australia[10] and Spain[11] revealed that misoprostol is effective 
in evacuating the uterus of first trimester missed abortion 
in 80% and 90% of cases, respectively. However, Panta et al.[3] 
in Sarilanka reported an effectiveness rate of 95%, whereas 
Ngoc et al. in Vietnam recorded a rate of 93%.[12]
In sub‑Saharan Africa, including Nigeria, studies on 
misoprostol in first trimester abortion are few and most of 
them report its effectiveness in incomplete abortion.[1,9,13‑15] 
The Nigerian multicentic study[15] revealed that over 98% of 
Nigerian women preferred misoprostol to manual vacuum 
aspiration (MVA) in the management of incomplete abortion. 
Side effects reported in most studies were minor and 
transient and include nausea/vomiting and shivering.[2,10‑16]
Data on the effectiveness of misoprostol in missed abortion 
in sub‑Saharan Africa are very scarce. In this article, we 
document the effectiveness of misoprostol in the evacuation 
of first trimester missed/delayed abortion in a tertiary care 
center in Bauchi, north‑eastern Nigeria.
Materials and Methods
This study was a prospective study (non‑randomized 
trial) involving consecutive patients (stable and with no 
significant comorbidity) who presented to the gynecologic 
unit of Abubakar Tafawa Balewa University Teaching 
Hospital (ATBUTH) Bauchi with first trimester missed 
abortion from January to December 2013. From a case load 
of 1–2 per week, at least 50 patients were anticipated to be 
recruited into the study. ATBUTH is the only tertiary care/
referral facility in the central and southern parts of Bauchi 
State of Nigeria.
Protocol
Consented consecutive patients who presented with 
confirmed (by ultrasonography) first trimester missed 
abortion were recruited into the study. Each patient was 
given sublingual misoprostol 600 µg, which was repeated 
after 6 hours if the abortion process was not initiated. 
They were also offered contraceptive counseling, and 
were followed up after 2 weeks for clinical evaluation 
and contraceptive services. However, they were seen 
after 1 week if heavy vaginal bleeding persisted, and were 
offered pelvic scan/surgical evacuation with MVA (Ipas 
Plus). Telephone review was conducted for patients who 
defaulted follow‑up. Treatment failure was defined as 
either failure to initiate abortion after the maximum two 
doses or incomplete evacuation as evidenced by persistent 
heavy vaginal bleeding after 1 week (along with ultrasound 
evidence of retained products) or vaginal spotting after 
2 weeks of therapy with or without ultrasound evidence 
of incomplete evacuation). Data was entered in a 
proforma designed for the study and were analyzed using 
the Statistical Package for the Social Sciences version 17 
Misoprostol (Cytotec by Pfizer Pharmaceuticals). P value was 
set at <0.05 at 95% confidence interval.
Results
Sixty‑one patients with missed abortion in the first trimester 
(uterine size: ≤12 weeks) were recorded with a mean age 
of 27.7 ± 5.6 years (range: 17–44 years), mean parity 
of 3.6 ± 2.3 (range: 0–12) and mean gestational age 
7.6 ± 2.0 weeks (6–12 weeks). Fifty‑six patients had 
complete evacuation (92% evacuation rate), with 7 (12%) 
requiring second dose of misoprostol, and all showed 
satisfaction with the method and recommended it to their 
friends. Five patients (8.2%) had failed medical evacuation 
(1 completely unresponsive and 4 with incomplete 
evacuation), and thus underwent MVA. The mean interval 
between the first dose and abortion process was 5.1 ± 2.2 
hours (range: 2–10 hours), and mean duration of vaginal 
bleeding was 5.9 ± 1.6 days (range: 3–14 days).
There appeared to be no relationship between the interval 
for abortion or duration of vaginal bleeding with gestational 
age [Table 1]. Table 2 presents the side effects of misoprostol 
among the patients. Nausea/vomiting and rigors were the 
common side effects. Only 7 patients (11%) commenced 
contraception after evacuation, and 6 accepted combined 
pills and one injectable.
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Discussion
With a mean age of 27 years, our patients were relatively 
young, which is typical in most developing countries. The 
evacuation rate of 92% in this study is similar to most 
data from resource poor countries. It is comparable to the 
rate of 93% and 95% reported by Ngoc et al.[12] and Panta 
et al.[3] from Vietnam and Nepal, respectively, and the 90% 
rate reported by Barcelo et al. from Spain.[11] However, our 
rate is higher than the rate of 80% reported by Peterson et al. 
from Australia.[10] The differences in the evacuation rates 
may not be disconnected to the differences in the definition 
of successful emptying of the uterus, the dosing regimen 
and routes of administration of misoprostol. It should be 
noted that only 12% of our patients required repeat dose 
of misoprostol. This implies that over two‑third of patients 
require only one dose of misoprostol, underscoring the 
cost effectiveness of medical evacuation, especially in our 
setting where cost is a major barrier to accessing quality 
post‑abortion care services. The reported 12% rate for the 
requiring repeat dose of misoprostol was lower compared 
with the 40.5% rate reported by Peterson et al.[10] Considering 
environmental factors, differences in the study design and 
sample size may account for the wide difference in the rate 
for the requirement of repeat dose of misoprostol.
Our figures for the time interval for abortion process to 
commence and duration of vaginal bleeding (mean of 5.1 
hours and 6 days, respectively) are consistent with previous 
reports.[7,12,17]
Side effects of misoprostol recorded in this study were 
largely minor and self‑limiting‑nausea, vomiting, rigors 
and pyrexia. This is consistent with established data.[2,10,11] 
Satisfaction with medical evacuation with misoprostol was 
readily expressed by a majority of our patients in this study 
including recommending it to their friends. This observation 
is in conformity with previous reports from Africa.[13‑15,18]
The post‑abortion contraceptive rate documented in our 
study is very low compare with previous reports.[2,3,15] 
Post‑abortion contraception after medical abortion may pose 
some challenges in our environment largely because of the 
poor follow‑up among other factors. Research on how best to 
deliver contraceptive services following medical evacuation 
as part of post‑abortion care is a certainly a priority in our 
setting.
Conclusion
It can be concluded that misoprostol is effective and safe 
in the management of first trimester missed abortion and 
should be the first line of management in our setting. This 
is particularly pertinent at the primary health care facilities, 
which are largely manned by mid‑level personnel.
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